Automated prostate-extension grading shows a sensitivity–specificity tradeoff against pathology
Source check: Source checked. Not independent scientific confirmation.
Finding: A cascaded segmentation and random-forest pipeline was evaluated against surgical pathology in a retrospective prostate-cancer cohort. In 127 held-out patients, one threshold produced lower sensitivity but higher specificity than the radiologist comparison. This is a bounded clinical-validation finding, without established superiority, improved surgical decisions or independent replication of the reused segmentation model.
Technology: Reused 3D U-Net/residual segmentation pipeline with random-forest extraprostatic-extension grading
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Learned segmentation extracted lesion/capsule features and a trained random forest mapped them to extension grades; comparison with actual surgical pathology supplies the distinct clinical-validation result. This extends a previously developed segmentation workflow rather than constituting independent replication of it.
- Test and result
- The source split 634 prostatectomy patients into 507 development and 127 test patients. Fixed segmentation models produced prostate/lesion masks; geometric features trained random forests with repeated cross-validation. At EPE≥1, test sensitivity/specificity were 0.67/0.73 versus 0.81/0.62 for the radiologist, using pathology as reference. Four-grade balanced accuracy was limited, and individual grade AUCs ranged 0.55–0.70.
- Limitation / still unknown
- This retrospective analysis used prospectively recorded radiologist assessments, without prospective AI-model locking. Development grades partly incorporated pathology, while comparison grades came from the radiologist. Reused segmentation models and overlapping institutional recruitment periods mean the full pipeline is not established as wholly unfamiliar with test patients. No paired clinical reader-assistance or treatment-benefit trial was performed, and no general superiority is claimed.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC11490411/ · https://pmc.ncbi.nlm.nih.gov/articles/PMC10575564/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 21 Nov 2026. Review scope: Read actual primary clinical selection/patient split, radiologist/pathology label construction, fixed segmentation-feature and random-forest training/evaluation Methods, pathology-reference test Results and comparison limits. Source reference27 checked against previously read segmentation paper. Individual overlap across reused model training and this cohort not reconstructed. Exact original article front DOI/title and fresh PubMed primary relationship metadata checked..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.